Latest

2 stories

Hide weekly roundups

Tuesday, August 4

Quarterly updateHarmony Biosciences Holdings, Inc.pitolisant

Harmony Biosciences reports record WAKIX revenue, posts Phase 1 data for BP-205

WAKIX net revenue rose 30% to $261.3 million in Q2 2026 as Harmony released single ascending dose data for orexin-2 agonist BP-205 and reaffirmed full-year guidance.

SEC filing

Thursday, July 16

PeopleHarmony Biosciences Holdings, Inc.pitolisant

Harmony Biosciences preannounces record Q2 2026 revenue, CFO steps down

WAKIX net revenue reached roughly $261 million as Glenn Reicin departs and Stephen Mollichella becomes interim finance chief.

SEC filing